Resources with keywords: zika virus



Oropouche virus: Infectious substances pathogen safety data sheet
Public Health Agency of Canada
Oropouche virus VR-266
ATCC

ATCC is a repository of biological materials. This is a sample from Trinidad.

Important Information for Blood Establishments Regarding the Oropouche Virus and Blood Donation
FDA
13 September 2024

Worldwide, there have been no reports of transmission of OROV by transfusion of blood or blood components. FDA will continue to monitor cases of OROV disease in the U.S. and worldwide and will issue updated information as it becomes available.

FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus
FDA

From FDA’s Release: Ixchiq is administered as a single dose by injection into the muscle. It contains a live, weakened version of the chikungunya virus and may cause symptoms in the vaccine recipient similar to those experienced by people who have chikungunya disease.

IXCHIQ
FDA

Vaccine Information

Pathogen Safety Data Sheets: Infectious Substances – Chikungunya virus
Public Health Agency of Canada

Reference document on Chikungunya Virus

Chikungunya: CDC Yellow Book 2024

This chapter includes information on the agent, transmission, diagnosis, treatment, prevention, epidemiology

Zika Virus Vaccines
NIH

NIAID is developing multiple vaccine candidates to prevent Zika virus infection.

keywords: vaccines, zika virus
Zika Virus: For Healthcare Providers
CDC

clinical evaluation, sexual transmission, infection control

Zika virus: Symptoms and treatment
Government of Canada
keywords: zika virus
Go to Top